@article{a0ad83014876498c8ec757dce75b7925,
title = "Lower risk of severe checkpoint inhibitor toxicity in more advanced disease",
keywords = "checkpoint inhibition, immune-related adverse event (irAE), anti-PD1, melanoma, DMTR, IMMUNE CHECKPOINTS, ADVERSE EVENTS, CANCER, MELANOMA, IPILIMUMAB, IMMUNOTHERAPY, ASSOCIATION, MONOTHERAPY, NIVOLUMAB, SURVIVAL",
author = "Verheijden, {Rik J.} and May, {Anne M.} and Blank, {Christian U.} and {van der Veldt}, {Astrid A. M.} and Boers-Sonderen, {Marye J.} and Aarts, {Maureen J. B.} and {van den Berkmortel}, {Franchette W. P. J.} and {van den Eertwegh}, {Alfonsus J. M.} and {de Groot}, {Jan Willem B.} and {van der Hoeven}, {Jacobus J. M.} and Hospers, {Geke A. P.} and Djura Piersma and {van Rijn}, {Rozemarijn S.} and {ten Tije}, {Albert J.} and Gerard Vreugdenhil and {van Zeijl}, {Michiel C. T.} and Wouters, {Michel W. J. M.} and Haanen, {John B. A. G.} and Ellen Kapiteijn and Suijkerbuijk, {Karijn P. M.}",
year = "2020",
doi = "10.1136/esmoopen-2020-000945",
language = "English",
volume = "5",
journal = "ESMO Open",
issn = "2059-7029",
publisher = "BMJ Publishing Group",
number = "6",
}